Synergistic effect of survivin-specific small interfering RNA and topotecan in renal cancer cells: Topotecan enhances liposome-mediated transfection by increasing cellular uptake

International Journal of Oncology

Volumn 30, Issue 3, 2007, Pages 695-700

  Sato, Akinori ^a   Ito, Keiichi ^a   Asano, Takako ^a   Sumitomo, Makoto ^a   Asano, Tomohiko ^a   Hayakawa, Masamichi ^a  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

Author keywords

Lipofection; Renal cancer; siRNA; Survivin; Topotecan; Transfection efficiency

Indexed keywords

ANTINEOPLASTIC AGENT; BIRC5 PROTEIN, HUMAN; LIPOSOME; MICROTUBULE ASSOCIATED PROTEIN; SMALL INTERFERING RNA; TOPOTECAN; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BIOSYNTHESIS; CELL CYCLE; CELL PROLIFERATION; DOSE RESPONSE; FLOW CYTOMETRY; GENETIC TRANSFECTION; HUMAN; KIDNEY TUMOR; METABOLISM; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; HUMANS; KIDNEY NEOPLASMS; LIPOSOMES; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; RNA, SMALL INTERFERING; TOPOTECAN; TRANSFECTION;

EID: 33947728944     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.30.3.695     Document Type: Article

References (36)

1. Landis SH, Murray T, Bolden S and Wingo PA: Cancer statistics. CA Cancer J Clin 49: 8-31, 1999.
2. Fossa SD: Interferon in metastatic renal cell carcinoma. Semin Oncol 27: 187-193, 2000. (Pubitemid 30205373)
3. Mulders P, Figlin R, De Kernion JB, Wiltrout R, Linehan M, Parkinson D, De Wolf W and Belldegrun A: Renal cell carcinoma: recent progress and future directions. Cancer Res 57: 5189-5195, 1997.
4. Pittman K and Selby P: The management of renal cell carcinoma. Crit Rev Oncol Hematol 16: 181-200, 1994.
5. Mickisch GH: Immunotherapy of renal cell carcinoma. A critical appraisal from a urologist's point of view. Urol Int 63: 16-21, 1999.
6. Pyrhonen S, Salminen E, Ruutu M, Lehtonen T, Nurmi M, Tammela T, Juusela H, Rintala E, Hietanen P and Kellokumpu-Lehtinen PL: Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 17: 2859-2867, 1999.
7. Bacoyiannis C, Dimopoulos MA, Kalofonos HP, Nicolaides C, Aravantinos G, Bafaloukos D, Samelis G, Onyenadum A, Kiamouris Ch, Skarlos D, Pavlidis N, Triantafillidis A and Kosmidis P; Hellenic Cooperative Oncology Group: Vinblastine and interferon-gamma combination with and without 13-cis retinoic acid for patients with advanced renal cell carcinoma. results of two phase II clinical trials. Oncology 63: 130-138, 2002.
8. Ambrosini G, Adida C and Altieri DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3: 917-921, 1997.
9. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC and Altieri DC: Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396: 580-584, 1998.
10. Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T and Reed JC: IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 58: 5315-5320, 1998.
11. La Casse EC, Baird S, Korneluk RG and MacKenzie AE: The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 17: 3247-3259, 1998.
12. Ambrosini G, Adida C, Sirugo G and Altieri DC: Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting. J Biol Chem 273: 11177-11182, 1998.
13. Olie RA, Simoes-Wust AP, Baumann B, Leech SH, Fabbro D, Stahel RA and Zangemeister-Wittke U: A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res 60: 2805-2809, 2000.
14. Kappler M, Bache M, Bartel F, Kotzsch M, Panian M, Wurl P, Blumke K, Schmidt H, Meye A and Taubert H: Knockdown of survivin expression by small interfering RNA reduces the clonogenic survival of human sarcoma cell lines independently of p53. Cancer Gene Ther 11: 186-193, 2004.
15. Sato A, Oya M, Ito K, Mizuno R, Horiguchi Y, Umezawa K, Hayakawa M and Murai M: Survivin associates with cell proliferation in renal cancer cells: Regulation of survivin expression by insulin-like growth factor-1, interferon-γ and a novel NF-κB inhibitor. Int J Oncol 28: 841-846, 2006.
16. Vindelov LL, Christensen IJ and Nissen NI: A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry 3: 323-327, 1983.
17. Hannon GJ: RNA interference. Nature 11: 244-251, 2002.
18. Sorensen DR, Leirdal M and Sioud M: Gene silencing by systemic delivery of synthetic siRNAs in adult mice. J Mol Biol 327: 761-766, 2003.
19. Ling X, Bernacki RJ, Brattain MG and Li F: Induction of survivin expression by taxol (paclitaxel) is an early event, which is independent of taxol-mediated G2/M arrest. J Biol Chem 279: 15196-15203, 2004.
20. Altieri DC: Cytokinesis, apoptosis and survivin: three for tango? Cell Death Differ 8: 4-5, 2001.
21. Law TM, Ilson DH and Motzer RJ: Phase II trial of topotecan in patients with advanced renal cell carcinoma. Invest New Drugs 12: 143-145, 1994.
22. Ramp U, Mahotka C, Kalinski T, Ebel E, Gabbert HE and Gerharz CD: Topotecan (Hycamtin) responsiveness in human renal carcinoma cell lines of the clear cell and papillary types. Anticancer Res 21: 3509-3517, 2001.
23. Giovannetti E, Mey V, Danesi R, Basolo F, Barachini S, Deri M and Del Tacca M: Interaction between gemcitabine and topotecan in human non-small-cell lung cancer cells: effects on cell survival, cell cycle and pharmacogenetic profile. Br J Cancer 92: 681-689, 2005.
24. Ohneseit PA, Prager D, Kehlbach R and Rodemann HP: Cell cycle effects of topotecan alone and in combination with irradiation. Radiother Oncol 75: 237-245, 2005.
25. Griffith TS and Kemp TJ: The topoisomerase I inhibitor topotecan increases the sensitivity of prostate tumor cells to TRAIL/Apo-2L-induced apoptosis. Cancer Chemother Pharmacol 52: 175-184, 2003.
26. Li S and Huang L: Non-viral gene therapy: promises and challenges. Gene Ther 7: 31-34, 2000.
27. Fujimaki K, Aratani Y, Fujisawa S, Motomura S, Okubo T and Koyama H: DNA topoisomerase II inhibitors enhance random integration of transfected vectors into human chromosomes. Somat Cell Mol Genet 22: 279-290, 1996.
28. Koster F, Felberbaum R, Finas D, Wunsch K, Schulz C, Diedrich K and Hauser C: Progesterone and estradiol enhance lipid mediated transfection of Sk-Br-3 mammalian cancer cells. Int J Mol Med 9: 617-620, 2002.
29. Ohmiya N, Emi N, Niwa Y, Goto H and Hayakawa T: Insulin-enhanced liposome-mediated gene transfer into a gastric carcinoma cell line. Clin Exp Pharmacol Physiol 29: 544-548, 2002.
30. Harrington KJ, Rowlinson-Busza G, Syrigos KN, Uster PS, Vile RG, Peters AM and Stewart JS: The effect of irradiation on the biodistribution of radiolabeled pegylated liposomes. Int J Radiat Oncol Biol Phys 50: 809-820, 2001.
31. Saxena A, Yashar C, Taylor DD and Gercel-Taylor C: Cellular response to chemotherapy and radiation in cervical cancer. Am J Obstet Gynecol 192: 1399-1403, 2005.
32. Ikeguchi M and Kaibara N: Changes in survivin messenger RNA level during cisplatin treatment in gastric cancer. Int J Mol Med 8: 661-666, 2001.
33. Azuhata T, Scott D, Takamizawa S, Wen J, Davidoff A, Fukuzawa M and Sandler A: The inhibitor of apoptosis protein survivin is associated with high-risk behavior of neuroblastoma. J Pediatr Surg 36: 1785-1791, 2001.
34. Rodel F, Hoffmann J, Distel L, Herrmann M, Noisternig T, Papadopoulos T, Sauer R and Rodel C: Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer Res 65: 4881-4887, 2005.
35. Fuessel S, Herrmann J, Ning S, Kotzsch M, Kraemer K, Schmidt U, Hakenberg OW, Wirth MP and Meye A: Chemosensitization of bladder cancer cells by survivin-directed antisense oligodeoxynucleotides and siRNA. Cancer Lett 232: 243-254, 2006.
36. Pennati M, Binda M, De Cesare M, Pratesi G, Folini M, Citti L, Daidone MG, Zunino F and Zaffaroni N: Ribozyme-mediated down-regulation of survivin expression sensitizes human melanoma cells to topotecan in vitro and in vivo. Carcinogenesis 25: 1129-1136, 2004.